UBS analyst David Lai lowered the firm’s price target on Perspective Therapeutics (CATX) to $7 from $18 and keeps a Buy rating on the shares. The Q3 press release highlighted upcoming data updates in 1H26 for lead program VMT-alpha-NET, with the firm saying we should expect an additional 23 patients as early as Q1 as well as durability from existing patients. The firm added that it believes increased competition may impact commercial adoption of VMT-alpha-NET.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CATX:
- Perspective Therapeutics price target lowered to $11 from $12 at B. Riley
- Perspective Therapeutics Reports Q3 2025 Results and Clinical Progress
- Positive Outlook for Perspective Therapeutics Amidst Key Catalysts and Financial Resilience
- Buy Rating for Perspective Therapeutics: Promising Pipeline and Financial Stability
- Buy Rating for Perspective Therapeutics: Promising Pb-212 Pipeline and Acquisition Potential